An investigation on the anti-tumor properties of FSH33-53-Lytic
An investigation on the anti-tumor properties of FSH33-53-Lytic
复制标题
DOI：
10.1007/s10967-015-4143-0
复制
发表时间：
2015
影响因子：
1.6
通讯作者：
Ping Liu;Runlin Yang;D. Pan;Yu-ping Xu;Chen Zhu;Qing Xu;Li-zhen Wang;Junjie Yan;Xiaotian Li;Min Yang
中科院分区：
文献类型：
--
作者：
Ping Liu;Runlin Yang;D. Pan;Yu-ping Xu;Chen Zhu;Qing Xu;Li-zhen Wang;Junjie Yan;Xiaotian Li;Min Yang
合成了一种新的杂合肽FSH 33 -53-Lytic，有望将促卵泡激素受体（FSHR）靶向和肿瘤细胞膜崩解结合起来。通过体外和体内研究，与单独的裂解肽相比，没有显示出显著的抗肿瘤活性增强。我们还对18F-Al-NOTA-MAL-FSH 33 -53-Lytic进行了标记，并利用microPET图像观察了FSH 33 -53-Lytic对FSHR的靶向性。肿瘤中无蓄积可以解释FSH 33 -53-Lytic在癌症治疗中的失败。总之，microPET图像可以为筛选新的抗肿瘤药物提供更准确、更直观的信息。
A new designed hybrid peptide FSH33-53-Lytic was synthesized and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor cell membranes disintegration. Through in vitro and vivo study, no significant enhancement on anti-tumor activity was shown compared with Lytic peptide only. We also prepared18F-Al-NOTA-MAL-FSH33-53-Lytic and use microPET image to observe the FSHR targeting of FSH33-53-Lytic. No accumulation in the tumor may explain the failure of FSH33-53-Lytic on cancer therapy. In summary, microPET image can provide more accurate and visible information for screening new anti-tumor agents.